CA3223130A1 - Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency - Google Patents
Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency Download PDFInfo
- Publication number
- CA3223130A1 CA3223130A1 CA3223130A CA3223130A CA3223130A1 CA 3223130 A1 CA3223130 A1 CA 3223130A1 CA 3223130 A CA3223130 A CA 3223130A CA 3223130 A CA3223130 A CA 3223130A CA 3223130 A1 CA3223130 A1 CA 3223130A1
- Authority
- CA
- Canada
- Prior art keywords
- piperidine
- trifluoromethyl
- carboxylic acid
- phenyl
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108523.8A GB202108523D0 (en) | 2021-06-15 | 2021-06-15 | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
| GB2108523.8 | 2021-06-15 | ||
| PCT/GB2022/051502 WO2022263816A1 (en) | 2021-06-15 | 2022-06-15 | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3223130A1 true CA3223130A1 (en) | 2022-12-22 |
Family
ID=76954605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223130A Pending CA3223130A1 (en) | 2021-06-15 | 2022-06-15 | Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12673050B2 (enExample) |
| EP (1) | EP4355328A1 (enExample) |
| JP (1) | JP7854001B2 (enExample) |
| KR (1) | KR20240027693A (enExample) |
| CN (1) | CN117794538A (enExample) |
| AU (1) | AU2022295130A1 (enExample) |
| BR (1) | BR112023026510A2 (enExample) |
| CA (1) | CA3223130A1 (enExample) |
| GB (1) | GB202108523D0 (enExample) |
| IL (1) | IL309355A (enExample) |
| MX (1) | MX2023015398A (enExample) |
| WO (1) | WO2022263816A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201918410D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2071621C (en) | 1991-06-19 | 1996-08-06 | Ahihiko Hosoda | Aldehyde derivatives |
| JP3391038B2 (ja) | 1991-12-26 | 2003-03-31 | 富士レビオ株式会社 | カルボン酸アミド誘導体 |
| WO2005113542A2 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| WO2008143633A2 (en) | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| US8258158B2 (en) | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| WO2011110852A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide |
| WO2012097371A2 (en) * | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis |
| CN110325527B (zh) | 2016-12-09 | 2022-08-09 | 勃林格殷格翰国际有限公司 | 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺 |
| CA3103920C (en) | 2018-06-22 | 2025-09-16 | Ucl Business Ltd | COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN |
| JOP20210060A1 (ar) | 2018-10-05 | 2023-01-30 | Vertex Pharma | معدلات لمضاد تريبسين ألفا-1 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| GB201918410D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
-
2021
- 2021-06-15 GB GBGB2108523.8A patent/GB202108523D0/en not_active Ceased
-
2022
- 2022-06-15 CN CN202280053656.2A patent/CN117794538A/zh active Pending
- 2022-06-15 IL IL309355A patent/IL309355A/en unknown
- 2022-06-15 MX MX2023015398A patent/MX2023015398A/es unknown
- 2022-06-15 JP JP2023577946A patent/JP7854001B2/ja active Active
- 2022-06-15 WO PCT/GB2022/051502 patent/WO2022263816A1/en not_active Ceased
- 2022-06-15 CA CA3223130A patent/CA3223130A1/en active Pending
- 2022-06-15 KR KR1020247001332A patent/KR20240027693A/ko active Pending
- 2022-06-15 BR BR112023026510A patent/BR112023026510A2/pt unknown
- 2022-06-15 AU AU2022295130A patent/AU2022295130A1/en active Pending
- 2022-06-15 EP EP22735956.9A patent/EP4355328A1/en active Pending
-
2023
- 2023-12-14 US US18/540,695 patent/US12673050B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7854001B2 (ja) | 2026-04-30 |
| US12673050B2 (en) | 2026-07-07 |
| JP2024523406A (ja) | 2024-06-28 |
| US20240197707A1 (en) | 2024-06-20 |
| AU2022295130A1 (en) | 2024-01-18 |
| MX2023015398A (es) | 2024-04-29 |
| GB202108523D0 (en) | 2021-07-28 |
| BR112023026510A2 (pt) | 2024-03-05 |
| CN117794538A (zh) | 2024-03-29 |
| KR20240027693A (ko) | 2024-03-04 |
| IL309355A (en) | 2024-02-01 |
| EP4355328A1 (en) | 2024-04-24 |
| WO2022263816A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12221422B2 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| US20240197707A1 (en) | Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency | |
| US12611402B2 (en) | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | |
| US12286402B2 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| JP2006504646A (ja) | ８−ヒドロキシキノリン誘導体 | |
| US20230102488A1 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| HK40079913B (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| HK40079913A (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| CA3164304A1 (en) | Compounds and their use for the treatment of .alpha.1-antitrypsin deficiency | |
| WO2022263817A1 (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| HK40076778B (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | |
| HK40076778A (en) | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251205 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260202 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260619 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST Effective date: 20260625 |